Investment value finders Investment value finders
This story originally appeared on The Growth Op.
Ontario’s MediPharm Labs Corp. has launched a new line of THC-free, 99 per cent pure CBD crystalline isolate to be sold under the LABS Cannabis banner.
According to a press release, it’s the first product of its kind in Canada.
“Produced at commercial scale, LABS Cannabis CBD Isolate has only trace amounts of THC — less than 0.2 per cent — which makes it an excellent choice for a broad range of wellness consumers and patients seeking the potential benefits of CBD without the intoxicating effects of THC,” Pat McCutcheon, CEO of MediPharm Labs, says in a statement.
Pat McCutcheon says the product is the right choice “for consumers who wish to consume CBD as part of their daily regimen or for specialized pediatric care in situations where CBD has been prescribed by a physician for a specific indication.”
MediPharm is hoping the product will resonate with consumers focused on health and wellness. A Health Canada report released earlier this year found that nearly 70 per cent of respondents (about 1,100 people) were interested in “cannabis health products,” particularly to treat pain and inflammation.
They also “expressed a strong interest in CBD.” Seniors, veterans, athletes and women experiencing menopause were all groups of interest.
Each container of the new product contains 500 mg of CBD in an odourless powder form. According to McCutcheon, the product has the “highest purity of all currently available concentrate formats,” making it “an incredibly versatile and valued ingredient for consumers.”
The company was founded in 2015 and specializes in cannabis concentrates and derivative products. According to a press release, the CBD isolate will be available from retailers nationwide.
